Botanix Pharmaceuticals Ltd (BOT) - Net Assets
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has net assets worth AU$81.30 Million AUD (≈ $57.52 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$129.10 Million ≈ $91.34 Million USD) and total liabilities (AU$47.80 Million ≈ $33.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Botanix Pharmaceuticals Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$81.30 Million |
| % of Total Assets | 62.98% |
| Annual Growth Rate | 5.4% |
| 5-Year Change | 290.86% |
| 10-Year Change | 2455.84% |
| Growth Volatility | 658.2 |
Botanix Pharmaceuticals Ltd - Net Assets Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. See Botanix Pharmaceuticals Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Botanix Pharmaceuticals Ltd (1989–2025)
The table below shows the annual net assets of Botanix Pharmaceuticals Ltd from 1989 to 2025. For live valuation and market cap data, see Botanix Pharmaceuticals Ltd (BOT) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$81.30 Million ≈ $57.52 Million |
-25.23% |
| 2024-06-30 | AU$108.73 Million ≈ $76.94 Million |
+373.76% |
| 2023-06-30 | AU$22.95 Million ≈ $16.24 Million |
+181.55% |
| 2022-06-30 | AU$8.15 Million ≈ $5.77 Million |
-60.81% |
| 2021-06-30 | AU$20.80 Million ≈ $14.72 Million |
-12.00% |
| 2020-06-30 | AU$23.64 Million ≈ $16.72 Million |
+3742.03% |
| 2019-06-30 | AU$615.22K ≈ $435.30K |
-96.22% |
| 2018-06-30 | AU$16.28 Million ≈ $11.52 Million |
+199.53% |
| 2017-06-30 | AU$5.44 Million ≈ $3.85 Million |
+70.92% |
| 2016-06-30 | AU$3.18 Million ≈ $2.25 Million |
+158.83% |
| 2015-06-30 | AU$1.23 Million ≈ $869.58K |
-45.22% |
| 2014-06-30 | AU$2.24 Million ≈ $1.59 Million |
+189.70% |
| 2013-06-30 | AU$-2.50 Million ≈ $-1.77 Million |
-7.18% |
| 2012-06-30 | AU$-2.33 Million ≈ $-1.65 Million |
-4.59% |
| 2011-06-30 | AU$-2.23 Million ≈ $-1.58 Million |
-24.19% |
| 2010-06-30 | AU$-1.80 Million ≈ $-1.27 Million |
-304.69% |
| 2009-06-30 | AU$877.74K ≈ $621.06K |
-31.75% |
| 2008-06-30 | AU$1.29 Million ≈ $909.99K |
-55.60% |
| 2007-06-30 | AU$2.90 Million ≈ $2.05 Million |
+30.25% |
| 2006-06-30 | AU$2.22 Million ≈ $1.57 Million |
-35.66% |
| 2005-06-30 | AU$3.46 Million ≈ $2.45 Million |
+54.00% |
| 2004-06-30 | AU$2.24 Million ≈ $1.59 Million |
-15.26% |
| 2003-06-30 | AU$2.65 Million ≈ $1.87 Million |
-34.56% |
| 2002-06-30 | AU$4.05 Million ≈ $2.86 Million |
-28.93% |
| 2001-06-30 | AU$5.69 Million ≈ $4.03 Million |
+10.57% |
| 2000-06-30 | AU$5.15 Million ≈ $3.64 Million |
-36.29% |
| 1999-06-30 | AU$8.08 Million ≈ $5.72 Million |
-48.68% |
| 1998-06-30 | AU$15.75 Million ≈ $11.15 Million |
-50.85% |
| 1997-06-30 | AU$32.05 Million ≈ $22.67 Million |
-15.47% |
| 1996-06-30 | AU$37.91 Million ≈ $26.83 Million |
-1.37% |
| 1995-06-30 | AU$38.44 Million ≈ $27.20 Million |
+47.60% |
| 1994-06-30 | AU$26.04 Million ≈ $18.43 Million |
+41.96% |
| 1993-06-30 | AU$18.35 Million ≈ $12.98 Million |
+60.85% |
| 1992-06-30 | AU$11.41 Million ≈ $8.07 Million |
-11.41% |
| 1991-06-30 | AU$12.88 Million ≈ $9.11 Million |
+7.64% |
| 1990-06-30 | AU$11.96 Million ≈ $8.46 Million |
-2.32% |
| 1989-06-30 | AU$12.24 Million ≈ $8.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Botanix Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28450.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$226.30 Million | 278.36% |
| Other Comprehensive Income | AU$32.18 Million | 39.59% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$81.30 Million | 100.00% |
Botanix Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daewoo Elec Co
KO:009320
|
$32.07 Million |
|
NATUZZI S.P.A. ADR/5 EO 1
F:NTZA
|
$32.09 Million |
|
Seafire AB
ST:SEAF
|
$32.09 Million |
|
Namibia Critical Metals Inc
V:NMI
|
$32.10 Million |
|
Display Tech Co. Ltd
KQ:066670
|
$32.07 Million |
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
$32.06 Million |
|
Asia Metal Public Company Limited
BK:AMC
|
$32.02 Million |
|
Nordic Iron Ore
ST:NIO
|
$32.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Botanix Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 108,732,549 to 81,298,929, a change of -27,433,620 (-25.2%).
- Net loss of 86,396,186 reduced equity.
- Share repurchases of 2,538,675 reduced equity.
- New share issuances of 40,462,000 increased equity.
- Other comprehensive income increased equity by 20,980,907.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-86.40 Million | -106.27% |
| Share Repurchases | AU$2.54 Million | -3.12% |
| Share Issuances | AU$40.46 Million | +49.77% |
| Other Comprehensive Income | AU$20.98 Million | +25.81% |
| Other Changes | AU$58.33K | +0.07% |
| Total Change | AU$- | -25.23% |
Book Value vs Market Value Analysis
This analysis compares Botanix Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | AU$15.75 | AU$0.02 | x |
| 1990-06-30 | AU$15.33 | AU$0.02 | x |
| 1991-06-30 | AU$16.51 | AU$0.02 | x |
| 1992-06-30 | AU$14.99 | AU$0.02 | x |
| 1993-06-30 | AU$16.93 | AU$0.02 | x |
| 1994-06-30 | AU$25.74 | AU$0.02 | x |
| 1995-06-30 | AU$48.76 | AU$0.02 | x |
| 1996-06-30 | AU$49.83 | AU$0.02 | x |
| 1997-06-30 | AU$42.12 | AU$0.02 | x |
| 1998-06-30 | AU$20.82 | AU$0.02 | x |
| 1999-06-30 | AU$32.32 | AU$0.02 | x |
| 2000-06-30 | AU$6.77 | AU$0.02 | x |
| 2001-06-30 | AU$14.96 | AU$0.02 | x |
| 2002-06-30 | AU$10.64 | AU$0.02 | x |
| 2003-06-30 | AU$6.96 | AU$0.02 | x |
| 2004-06-30 | AU$5.90 | AU$0.02 | x |
| 2005-06-30 | AU$12.40 | AU$0.02 | x |
| 2006-06-30 | AU$5.35 | AU$0.02 | x |
| 2007-06-30 | AU$6.20 | AU$0.02 | x |
| 2008-06-30 | AU$2.47 | AU$0.02 | x |
| 2009-06-30 | AU$1.54 | AU$0.02 | x |
| 2010-06-30 | AU$-0.28 | AU$0.02 | x |
| 2011-06-30 | AU$-0.33 | AU$0.02 | x |
| 2012-06-30 | AU$-0.61 | AU$0.02 | x |
| 2013-06-30 | AU$-0.59 | AU$0.02 | x |
| 2014-06-30 | AU$0.05 | AU$0.02 | x |
| 2015-06-30 | AU$0.01 | AU$0.02 | x |
| 2016-06-30 | AU$0.02 | AU$0.02 | x |
| 2017-06-30 | AU$0.01 | AU$0.02 | x |
| 2018-06-30 | AU$0.03 | AU$0.02 | x |
| 2019-06-30 | AU$0.00 | AU$0.02 | x |
| 2020-06-30 | AU$0.03 | AU$0.02 | x |
| 2021-06-30 | AU$0.02 | AU$0.02 | x |
| 2022-06-30 | AU$0.01 | AU$0.02 | x |
| 2023-06-30 | AU$0.02 | AU$0.02 | x |
| 2024-06-30 | AU$0.07 | AU$0.02 | x |
| 2025-06-30 | AU$0.04 | AU$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Botanix Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1492.37%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.59x
- Recent ROE (-106.27%) is above the historical average (-129.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -0.60% | -0.38% | 0.79x | 2.01x | AU$-1.27 Million |
| 1990 | -0.76% | -0.42% | 0.82x | 2.19x | AU$-1.26 Million |
| 1991 | -0.49% | -0.24% | 0.93x | 2.18x | AU$-1.32 Million |
| 1993 | -6.98% | -2.72% | 0.87x | 2.95x | AU$-2.19 Million |
| 1994 | -7.29% | -3.17% | 0.93x | 2.48x | AU$-3.39 Million |
| 1995 | -0.63% | -0.35% | 0.98x | 1.84x | AU$-3.94 Million |
| 1997 | 0.41% | 0.33% | 0.81x | 1.57x | AU$-3.07 Million |
| 1998 | 0.54% | 0.00% | 0.00x | 1.92x | AU$-1.50 Million |
| 1999 | -1.05% | 0.00% | 0.00x | 2.00x | AU$-893.40K |
| 2000 | -61.59% | -34.69% | 1.74x | 1.02x | AU$-3.69 Million |
| 2001 | -6.20% | -68.02% | 0.09x | 1.03x | AU$-922.47K |
| 2002 | -34.84% | -381.72% | 0.08x | 1.11x | AU$-1.81 Million |
| 2003 | -52.82% | -151.18% | 0.31x | 1.11x | AU$-1.66 Million |
| 2004 | -42.71% | -209.52% | 0.19x | 1.08x | AU$-1.18 Million |
| 2005 | 0.06% | 242.82% | 0.00x | 1.07x | AU$-340.92K |
| 2006 | -125.09% | -2991.40% | 0.04x | 1.13x | AU$-3.00 Million |
| 2007 | -117.96% | -6700.00% | 0.01x | 1.21x | AU$-3.71 Million |
| 2008 | -219.66% | -8071.43% | 0.01x | 1.84x | AU$-2.95 Million |
| 2009 | -346.69% | -33811.11% | 0.00x | 2.30x | AU$-3.13 Million |
| 2010 | 0.00% | -198900.00% | 0.02x | 0.00x | AU$-1.81 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.30 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.33 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.60 Million |
| 2014 | -50.41% | 0.00% | 0.00x | 1.14x | AU$-1.36 Million |
| 2015 | -82.59% | -2355.53% | 0.03x | 1.07x | AU$-1.14 Million |
| 2016 | -53.70% | 0.00% | 0.00x | 1.16x | AU$-2.03 Million |
| 2017 | -87.79% | -10264.52% | 0.01x | 1.09x | AU$-5.32 Million |
| 2018 | -67.62% | -619.35% | 0.10x | 1.09x | AU$-12.64 Million |
| 2019 | -2769.60% | -363.62% | 0.90x | 8.45x | AU$-17.10 Million |
| 2020 | -70.78% | -220.90% | 0.30x | 1.07x | AU$-19.09 Million |
| 2021 | -16.03% | -48.41% | 0.31x | 1.06x | AU$-5.41 Million |
| 2022 | -161.57% | -478.08% | 0.20x | 1.72x | AU$-13.99 Million |
| 2023 | -39.88% | -1000.47% | 0.04x | 1.08x | AU$-11.45 Million |
| 2024 | -12.76% | -2304.68% | 0.01x | 1.03x | AU$-24.74 Million |
| 2025 | -106.27% | -1492.37% | 0.04x | 1.59x | AU$-94.53 Million |
Industry Comparison
This section compares Botanix Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,254,417
- Average return on equity (ROE) among peers: -80.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Botanix Pharmaceuticals Ltd (BOT) | AU$81.30 Million | -0.60% | 0.59x | $32.07 Million |
| Adalta Ltd (1AD) | $10.62 Million | -10.96% | 0.01x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $5.31 Million | -39.43% | 0.03x | $15.75 Million |
| ACRUX Ltd (ACR) | $11.28 Million | 0.00% | 0.07x | $4.36 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $71.97 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $10.00 Million |
| Arovella Therapeutics Ltd (ALA) | $6.11 Million | -1.30% | 0.00x | $59.87 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.92 Million |
| Alterity Therapeutics Ltd (ATH) | $37.69 Million | -35.37% | 0.10x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $39.47 Million | -19.53% | 0.05x | $39.95 Million |
| Avecho Biotechnology Ltd (AVE) | $5.45 Million | -398.12% | 0.01x | $35.23 Million |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more